Pharmacosmos Holding A/S v American Regent, Inc

Link copied
Case Copied 37 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Pharmacosmos Holding A/S v American Regent, Inc. [2020] APO 36

Patent Application:                2016205002

Title:Methods and compositions for administration of iron

Patent Applicant:                   American Regent, Inc.

Opponent:  Pharmacosmos Holding A/S

Delegate:  Dr A. Lim

Decision Date:  29 July 2020

Hearing Date:  03 June 2020, via video conference

Catchwords:  PATENTS – opposition under section 104 – allowability under subsections 102(1) and 102(2) considered – “as a result of the amendments” – whether as a result of the amendment, “the skilled person is being presented with any new information about the invention which is not directly and unambiguously apparent from the original disclosure” – whether as a result of the amendments, the specification does not provide a clear enough and complete enough disclosure – whether as a result of the amendments, the claims are not supported, not clear or not succinct – amendments allowable – cost awarded against the opponent

Representation:  Patent attorney for the applicant: Houlihan2 Pty Ltd by written submissions only

Patent attorney for the opponent: Griffith Hack by written submissions and video conference

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2016205002

Title:Methods and compositions for administration of iron

Patent Applicant:                   American Regent, Inc.

Date of Decision:                   29 July 2020

DECISION

The opposition is unsuccessful on all grounds.

I allow the amendments filed on 24 April 2019.

Cost according to Schedule 8 are awarded against Pharmacosmos Holding A/S.

REASONS FOR DECISION

1.  Background

  1. Patent application number 2016205002 (the application) was filed on 18 July 2016 as a divisional application from 2013206429 (the parent application) which is in turn a divisional from 2007205167.  The application claims an earliest priority date of 06 January 2006 (the priority date).  The application was originally filed in the name of Luitpold Pharmaceuticals, Inc.  On 04 February 2019, the application was assigned to American Regent, Inc. (American) who are now the applicant.

  2. The application was examined and advertised accepted by the Commissioner on 01 February 2018. The grant of a patent was subsequently opposed under section 59 of the Patents Act 1990 (the Act) by Pharmacosmos Holding A/S (Pharmacosmos).  The opposition to the grant of a patent is still proceeding.

  3. American filed amendments on 24 April 2019 and leave to amend was advertised on 13 June 2019.  Pharmacosmos served a notice of opposition to the allowance of the amendments on 13 August 2019 and filed a statement of grounds and particulars (SGP) on 13 September 2019.  It is the opposition to the allowance of amendments (s104 opposition) only that is the subject of this decision.

  4. Accompanying the SGP, Pharmacosmos also filed a declaration by Dr Vito Ferro, dated 29 January 2019, and six other documents.  On 02 October 2019, the Commissioner issued a direction that any documents accompanying the SGP will be treated as evidence in support of the section 104 opposition.  Pharmacosmos filed no additional evidence in support.  American filed no evidence in answer.

    2.  The opposition

  5. The grounds of opposition pressed in written submissions and at the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pharmacosmos Holding A/S v American Regent, Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2020] APO 36
Decision Date

CaseChat Overview and Summary

Pharmacosmos Holding A/S opposed an Australian patent application held by American Regent, Inc. The dispute centred around the allowability of certain amendments made to the patent application under sections 102(1) and 102(2) of the Patents Act 1990. Pharmacosmos argued that the amendments did not meet the statutory requirements because they introduced new information not directly and unambiguously apparent from the original disclosure, failed to provide a clear and complete enough disclosure, and did not support the claims in a clear or succinct manner. The court was required to determine whether the amendments met the statutory criteria for allowability.

In examining the amendments, the court considered whether the changes presented new information not evident in the original disclosure, whether the specification sufficiently disclosed the invention post-amendment, and whether the claims were adequately supported. The court noted that the amendments did not introduce any new information that was not already implicit in the original disclosure. The court found that the specification, after amendment, provided a clear and complete enough disclosure, and the claims were supported in a clear and succinct manner. Consequently, the court held that the amendments were allowable under the statutory provisions.

The court concluded that the amendments were properly made and did not violate the statutory requirements for patentability. Given that the opposition was unsuccessful, the court awarded costs against Pharmacosmos, the party that had opposed the patent application. The decision underscores the importance of ensuring that any amendments to a patent application do not introduce new information, and that the specification and claims remain clear and supported by the disclosure.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established